Related references
Note: Only part of the references are listed.Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
M. M. Eatock et al.
ANNALS OF ONCOLOGY (2013)
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
M. Peeters et al.
BRITISH JOURNAL OF CANCER (2013)
VEGFA and tumour angiogenesis
L. Claesson-Welsh et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Which are the antibodies to watch in 2013?
Janice M. Reichert
MABS (2013)
Vascular Endothelial Growth Factor A in Intraocular Vascular Disease
Joan W. Miller et al.
OPHTHALMOLOGY (2013)
Molecular Determinants of Epidermal Growth Factor Binding: A Molecular Dynamics Study
Jeffrey M. Sanders et al.
PLOS ONE (2013)
Trial watch Monoclonal antibodies in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Susan Manzi et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Development of Anti-Infectives Using Phage Display: Biological Agents against Bacteria, Viruses, and Parasites
Johnny X. Huang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus
William Stohl et al.
ARTHRITIS AND RHEUMATISM (2012)
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2012)
Antibody Phage Display Libraries: Contributions to Oncology
Carmela Dantas-Barbosa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2012)
Which are the antibodies to watch in 2012?
Janice M. Reichert
MABS (2012)
Peptibodies A flexible alternative format to antibodies
Grant Shimamoto et al.
MABS (2012)
Solubility evaluation of murine hybridoma antibodies
Stacey Spencer et al.
MABS (2012)
Acute and Impaired Wound Healing: Pathophysiology and Current Methods for Drug Delivery, Part 2: Role of Growth Factors in Normal and Pathological Wound Healing: Therapeutic Potential and Methods of Delivery
Tatiana N. Demidova-Rice et al.
ADVANCES IN SKIN & WOUND CARE (2012)
Licensure of vaccines using the Animal Rule
Drusilla L. Burns
CURRENT OPINION IN VIROLOGY (2012)
Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?
William Stohl
CURRENT RHEUMATOLOGY REPORTS (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Evaluation of Protein Engineering and Process Optimization Approaches to Enhance Antibody Drug Manufacturability
Greg P. Conley et al.
BIOTECHNOLOGY AND BIOENGINEERING (2011)
Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development
Rodrigo Dienstmann et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Beyond natural antibodies: the power of in vitro display technologies
Andrew R. M. Bradbury et al.
NATURE BIOTECHNOLOGY (2011)
Antibodies Against Anthrax: Mechanisms of Action and Clinical Applications
Jeffrey W. Froude et al.
TOXINS (2011)
Effect of Long-Term Belimumab Treatment on B Cells in Systemic Lupus Erythematosus
Annett M. Jacobi et al.
ARTHRITIS AND RHEUMATISM (2010)
Phage display as a powerful tool to engineer protease inhibitors
Marie-Louise Zani et al.
BIOCHIMIE (2010)
Phage display: Concept, innovations, applications and future
Jyoti Pande et al.
BIOTECHNOLOGY ADVANCES (2010)
Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Kathlynn C. Brown
CURRENT PHARMACEUTICAL DESIGN (2010)
Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability
Jonathan A. Bernstein et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2010)
An improved manufacturing process for Xyntha/ReFacto AF
B. Kelley et al.
HAEMOPHILIA (2010)
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cross-Interaction Chromatography: A Rapid Method to Identify Highly Soluble Monoclonal Antibody Candidates
Steven A. Jacobs et al.
PHARMACEUTICAL RESEARCH (2010)
Structure-based engineering of a monoclonal antibody for improved solubility
Sheng-Jiun Wu et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
ECALLANTIDE: A PLASMA KALLIKREIN INHIBITOR FOR THE TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA
L. E. Stolz et al.
DRUGS OF TODAY (2010)
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
James B. Bussel et al.
BLOOD (2009)
Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Laetitia Devy et al.
CANCER RESEARCH (2009)
Engineered protein scaffolds as next-generation antibody therapeutics
Michaela Gebauer et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
Safety, Pharmacokinetics, and Antitumor Activity of AMG 386, a Selective Angiopoietin Inhibitor, in Adult Patients With Advanced Solid Tumors
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Raxibacumab for the Treatment of Inhalational Anthrax.
Thi-Sau Migone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma
Kusumam Joseph et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2008)
The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies
Christine Rothe et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:: a double-blind randomised controlled trial
David J. Kuter et al.
LANCET (2008)
Potential of phage-displayed peptide library technology to identify functional targeting peptides
Lauren R. H. Krumpe et al.
EXPERT OPINION ON DRUG DISCOVERY (2007)
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Engineering novel binding proteins from nonimmunoglobulin domains
HK Binz et al.
NATURE BIOTECHNOLOGY (2005)
Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity
RM Hoet et al.
NATURE BIOTECHNOLOGY (2005)
Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration
J Gaudreault et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
Selecting for antibody scFv fragments with improved stability using phage display with denaturation under reducing conditions
EC Brockmann et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2005)
Antibodies from phage antibody libraries
ARM Bradbury et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Isolation of a peptide ligand for affinity purification of factor VIII using phage display
BD Kelley et al.
JOURNAL OF CHROMATOGRAPHY A (2004)
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
J Oliner et al.
CANCER CELL (2004)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator
KP Baker et al.
ARTHRITIS AND RHEUMATISM (2003)
Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity
Z Zhu et al.
LEUKEMIA (2003)
DX-88 and HAE: a developmental perspective
A Williams et al.
TRANSFUSION AND APHERESIS SCIENCE (2003)
Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides
A Knappik et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Share Paper
